1. Top of page
  2. Abstract
  7. Acknowledgements


To explore the associations between measures of body composition derived from computed tomography (CT) of the thigh and functional outcomes in patients with rheumatoid arthritis (RA).


Patients with RA underwent bilateral midfemoral quantitative CT for measurement of thigh fat area (TFA), thigh muscle area (TMA), and thigh muscle density (TMD). The associations of thigh-composition measures with disability and physical performance, as measured with the Health Assessment Questionnaire (HAQ), the Valued Life Activities (VLAs), and the Short Physical Performance Battery (SPPB) instruments, were explored in the total cohort and in the cohort subgrouped by sex, controlling for pertinent demographic, lifestyle, and RA disease and treatment covariates.


A total of 152 RA patients were studied. Among the potential determinants of TMD, older age, longer duration of sedentary activity, longer duration of RA, higher tender joint count, higher serum interleukin-6 levels, use of glucocorticoids, and nonuse of hydroxychloroquine were all significantly associated with lower TMD in multivariable models. RA characteristics accounted for 63% of the explainable variability in TMD. When comodeled, higher TFA and lower TMD, but not lower TMA, were significantly and independently associated with higher HAQ scores, lower Short Form 36 health survey physical functioning scores, lower composite SPPB scores, and a greater proportion of affected obligatory VLAs.


Thigh CT–derived measures of body composition, particularly fat area and muscle density, were strongly associated with disability and physical performance in RA patients, with RA disease features as potential determinants. Efforts to reduce fat and improve muscle quality may reduce disability in this population with impaired physical functioning.

Rheumatoid arthritis (RA) is a systemic inflammatory disorder that affects 1–2% of adults and frequently leads to progressive joint deformity and disability. This disability is costly, with the direct medical cost of RA disability amounting to between $9,000 and $19,000 per year (1), and the indirect costs, such as loss of work, compounding the expense (2). In addition, greater disability in RA patients portends poorer health outcomes, including higher all-cause and cardiovascular mortality rates (3).

Contributors to disability in RA go beyond articular swelling, tenderness, and deformity. Several of the major extraarticular determinants include mood (4), sleep (5), and the more recently studied body composition. RA patients, on average, have lower body cell mass (6), lower lean mass (7), and higher fat mass (7, 8) as compared to otherwise similar non-RA controls. Lower lean mass and higher fat mass were independently associated with higher levels of disability in RA patients (9). However, distinct from the amount of muscle, the density of muscle may also affect physical functioning. Low muscle density, reflecting reduced muscle contractile units accompanied by fatty replacement (10, 11), was associated with aging, deconditioning, and disuse in the general population (12, 13). As these factors are features of the RA disease state, it is conceivable that low muscle density, in addition to—or even independent of—low muscle mass, may contribute to physical dysfunction in RA patients.

Computed tomography (CT) scanning at the level of the mid-thigh, with quantification of the areas and densities of fat, muscle, and bone, is a validated, reproducible technique for directly assessing whole and regional body composition (14–16). Studies of CT-assessed muscle density in the general population have shown it to be a suitable determinant of muscle quality, in terms of prediction of strength (17, 18), physical performance (18–20), and incidence of mobility limitations (21, 22). However, to date, there have been no studies using CT to assess muscle area or density in the RA population. Most studies have used indirect measures, such as bioelectrical impedance, total body dual x-ray absorptiometry (DXA), or potassium counting.

Therefore, in the present study, we explored the associations of RA disease characteristics with thigh muscle density (TMD), thigh muscle area (TMA), and thigh fat area (TFA), as assessed with quantitative CT. We hypothesized that low thigh muscle density would be associated with disability and low physical performance scores, independently of muscle and fat area.


  1. Top of page
  2. Abstract
  7. Acknowledgements

Study participants and timing of visits.

Study subjects were participants in the Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in Rheumatoid Arthritis (ESCAPE RA) study, a cohort study investigating the prevalence, progression, and risk factors for subclinical cardiovascular disease in RA (23). A total of 197 RA patients completed the baseline study visit, and all of them met the American College of Rheumatology 1987 classification criteria for RA (24), were 45–84 years of age, and did not report having any of the prespecified prior cardiovascular events or procedures. The study was approved by the Institutional Review Board of the Johns Hopkins Hospital. Thigh CT was performed at the third visit for the ESCAPE RA study, for which a total of 158 patients (80%) returned. This third study visit occurred an average of 39 ± 4 (±SD) months postbaseline.


Measurements of body composition.

Study participants underwent bilateral mid-thigh CT on the same Aquilion 64-slice CT scanner (Toshiba America Medical Systems). A single transverse section was obtained midway between the greater trochanter and the femoral condyles, localized using a coronal scout film. The scans were analyzed with BonAlyse software, which quantifies areas and densities of muscle, fat, and bone in operator-selected regions. To exclude artifacts and objects outside the patient, the outline of the thigh was traced manually by a technician (HRK) who was blinded with regard to the characteristics of the patients. TFA was defined as the quantity of tissue between −190 and −30 Hounsfield units and included both subcutaneous fat tissue and fat tissue intercalated between muscle tissues. Marrow-associated fat tissue was excluded from the TFA measurement.

Participants also underwent total body DXA on a Lunar Prodigy DXA scanner (GE/Lunar) to measure total and regional fat and lean mass. Anthropometric parameters (height, weight, body mass index [BMI], and waist and hip circumferences) were determined as previously described (25). The BMI was calculated as the body weight in kilograms divided by the square of the height in meters (kg/m2).

Determination of functional outcomes.

We assessed functional outcomes concurrently with the body composition assessments. The Stanford Health Assessment Questionnaire (HAQ) (26) and the physical functioning domain of the Short Form 36 (SF-36) health survey (27) were used to assess disability related to common activities. The HAQ has a range of 0–3, with higher HAQ scores indicating greater disability. The SF-36 physical functioning scores range from 0 to 100, with higher scores indicating less disability.

Physical performance was assessed using the extended Short Physical Performance Battery (SPPB) (28). The SPPB includes assessments of balance (side-by-side, semi-tandem, and one-leg stands), strength (single and repeated chair stands), and gait and endurance (usual and fast paced 6-meter and 400-meter walk tests). Scoring range is 0–4 based on completion/time for each of the 5 testing domains, for a total possible score of 20.

Disability in a broader range of activities, including activities outside of the fundamental physical actions assessed with HAQ, was assessed with the Valued Life Activities (VLA) questionnaire (29). This 29-item instrument assesses limitations in the patient's participation in obligatory activities (i.e., self-care, ambulation, transit; 4 items), committed activities (i.e., housework, preparing meals, shopping, care of family members; 10 items), and discretionary activities (i.e., traveling, leisure activities, recreation, socializing; 15 items) as a consequence of RA. Activities not engaged in by, or those unimportant to, the participant do not count toward the score.

Other assessments.

Age, sex, race/ethnicity, and history of current and past smoking were assessed by self-report. Forty-four joints were examined for swelling and tenderness by a single trained assessor, and RA disease activity was calculated using the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (30). Radiographs of the hands and feet were obtained and scored using the van der Heijde modification of the Sharp method (SHS) (31) by a single experienced reader who was blinded with regard to the patient's characteristics.

Physical activity was assessed with the 7-Day Physical Activity Recall Questionnaire (32), and the weekly total of physical activity for intentional exercise activities (moderate or brisk walking for exercise, and moderate or vigorous individual or team sports and conditioning activities) was calculated for each participant. The duration of television watching, a measure of sedentariness, was also assessed by self-report. Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression Scale (CES-D) (33). Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy (FACIT) questionnaire (34). Thyroid disease was classified based on the use of thyroid replacement therapy. Current and past use of glucocorticoids, biologic disease-modifying antirheumatic drugs (DMARDs), and non-biologic DMARDs was determined with the use of detailed examiner-administered questionnaires.

Laboratory assessments.

Blood samples were collected while the patient was in a fasting state, and the samples were stored at −80°C. CRP levels were measured by nephelometry and interleukin-6 (IL-6) by chemiluminescent enzyme immunoassay at the Laboratory for Clinical Biochemistry Research (University of Vermont, Burlington, VT). Rheumatoid factor (RF) was assessed by enzyme-linked immunosorbent assay (ELISA), with seropositivity defined as ≥40 units. Anti–cyclic citrullinated peptide (anti-CCP) antibody was assessed by ELISA, with seropositivity defined as ≥60 units. Exon 2 of HLA–DR1 was sequenced for shared epitope alleles as previously described (35).

Statistical analysis.

The distributions of all variables were examined. Univariate linear regression models were constructed to explore the associations of thigh composition outcomes with participant characteristics included as covariates, with calculations of beta coefficients, 95% confidence intervals (95% CIs), and their associated P values. Where required, variables were transformed to normality. To identify indicators of thigh fat and muscle measures, multivariable models were constructed with covariates carried over from univariate models that were significant at P ≤ 0.20 (to allow for residual confounding). More-parsimonious multivariable models were constructed by excluding covariates with the weakest associations with the outcome, with the impact of excluding each covariate tested using Akaike's Information Criterion for nested models. The adjusted coefficient of variability (R2) was used to estimate the total proportion of the variability in the outcome predicted by the modeled covariates. Variance inflation factors (VIFs) were calculated to ensure that variables with excessive collinearity were not modeled simultaneously.

To investigate the association of thigh fat and muscle measures with functional outcomes, multivariable models were constructed with functional measures modeled as outcomes and thigh composition measures modeled as exposures of interest. We considered covariates associated with both the thigh composition measures of interest and the functional outcomes to be confounding covariates. More-parsimonious multivariable models were constructed as described above. Spearman's correlation coefficients were calculated for correlations of anthropometric and DXA-derived body composition measures with functional outcomes as compared to correlations of thigh composition measures. All statistical calculations were performed using Intercooled Stata 10 (StataCorp). A two-tailed alpha value of 0.05 was used throughout.


  1. Top of page
  2. Abstract
  7. Acknowledgements

A total of 152 participants had thigh CTs suitable for body composition analysis. Characteristics of the 152 RA patients are summarized in Table 1. Participants were middle-aged or older (range 47–84 years; mean age 63 years), predominantly female (65%) and Caucasian (88%). On average, the cohort comprised patients with disease of longer duration (median 12 years) with current disease activity in the low-to-moderate range, although high disease activity (DAS28-CRP >5.1) was observed in 17 patients (11%). As a whole, the cohort reported mild-to-moderate disability (median HAQ score 0.69), achieved submaximal scores on physical performance testing (mean SPPB score 12 of a possible 20), and reported a median of 31% of their VLAs as being affected by their RA.

Table 1. Characteristics of 152 RA patients undergoing thigh fat and muscle composition assessment*
CharacteristicTotal (n = 152)Women (n = 98)Men (n = 54)P
  • *

    Except where indicated otherwise, values are the mean ± SD or the median (interquartile range). RA = rheumatoid arthritis; TV = television; CES-D = Center for Epidemiologic Studies Depression Scale; NA = not applicable; RF = rheumatoid factor; anti-CCP = anti–cyclic citrullinated peptide; DAS28-CRP = Disease Activity Score in 28 joints using the C-reactive protein level; IL-6 = interleukin-6; SHS = modified Sharp/van der Heijde score; VAS = visual analog scale; HAQ = Health Assessment Questionnaire; SF-36 = Short Form 36 health survey; VLAs = Valued Life Activities; DMARDs = disease-modifying antirheumatic drugs; TNF = tumor necrosis factor; CT = computed tomography; DXA = dual x-ray absorptiometry.

Demographic and clinical features    
 Age, mean ± SD years (range 47–84)63 ± 863 ± 862 ± 90.74
 Caucasian, no. (%)133 (88)84 (86)49 (91)0.37
 Any college, no. (%)118 (78)76 (78)42 (78)0.97
 Exercise, minutes/day29 (9–75)26 (6–62)51 (9–112)0.028
 TV watching, hours/day2 (1–3)2 (1–3)2 (1–3)0.66
 CES-D score5 (3–10)6 (3–11)5 (2–9)0.063
 Hormone replacement (women only), no. (%)9 (9)9 (9)NA
 Ever smoker, no. (%)81 (53)43 (44)38 (70)0.002
 Current smoker, no. (%)12 (8)5 (5)7 (13)0.085
 Thyroid disease, no. (%)26 (17)20 (20)6 (11)0.14
 Diabetes mellitus, no. (%)11 (7)7 (7)4 (7)0.97
RA-specific clinical features    
 RA duration, years12 (8–20)13 (7–20)10 (9–18)0.60
 RF or anti-CCP seropositivity, no. (%)113 (75)74 (76)39 (72)0.58
 Any shared epitope alleles, no. (%)105 (70)66 (68)39 (74)0.48
 DAS28-CRP3.1 (2.3–4.1)3.3 (2.7–4.3)2.5 (1.8–3.4)<0.001
 CRP, mg/liter2.4 (0.9–6.2)2.6 (1.1–7.4)2.3 (0.8–4.9)0.11
 IL-6, pg/ml4.3 (2.5–9.6)4.9 (2.5–10.4)3.8 (2.6–7.3)0.37
Health status assessments    
 Total SHS13 (3–53)20 (4–59)10 (2–29)0.16
 Pain, by 100-mm VAS20 (10–50)30 (10–50)10 (10–40)0.005
 HAQ score (range 0–3)0.69 (0.13–1.38)1.0 (0.38–1.38)0.19 (0–1.12)<0.001
 SF-36 physical functioning score64 ± 2661 ± 2571 ± 260.015
 Physical Performance Battery Score (range 0–20)12 ± 511 ± 514 ± 40.002
 Proportion of VLAs Affected0.31 (0.05–0.71)0.52 (0.17–0.75)0.09 (0–0.50)<0.001
  Obligatory VLAs0.20 (0–0.60)0.20 (0–0.75)0 (0–0.40)0.006
  Committed VLAs0.50 (0–0.86)0.60 (0.29–1.0)0.07 (0–0.67)<0.001
  Discretionary VLAs0.29 (0–0.69)0.50 (0.13–0.75)0.09 (0–0.43)<0.001
Medication use, no. (%)    
 Current prednisone38 (25)25 (26)13 (24)0.82
 Current nonbiologic DMARDs130 (86)88 (91)42 (78)0.028
  Methotrexate106 (70)74 (76)32 (59)0.028
  Hydroxychloroquine29 (19)20 (21)9 (17)0.56
 Current biologic DMARDs70 (46)54 (56)16 (30)0.002
  TNF inhibitors53 (35)40 (41)13 (24)0.034
Thigh CT–derived measures    
 Total thigh area, cm2201 ± 63204 ± 70196 ± 480.38
 Thigh muscle area, cm278 ± 3465 ± 24100 ± 36<0.001
 Thigh muscle density, mg/cm339 ± 539 ± 640 ± 40.23
 Thigh fat area, cm2124 ± 51139 ± 5496 ± 26<0.001
Anthropometric parameters    
 Weight, kg79 ± 1873 ± 1690 ± 16<0.001
 Height, meters1.66 ± 0.101.61 ± 0.061.74 ± 0.09<0.001
 Body mass index, kg/m228.5 ± 5.328.9 ± 5.729.4 ± 4.50.084
 Waist circumference, cm96 ± 1691 ± 16104 ± 13<0.001
 Waist-to-hip ratio0.91 ± 0.100.86 ± 0.071.01 ± 0.05<0.001
DXA-derived measures    
 Total body fat, kg31 ± 1132 ± 1229 ± 90.12
 Fat mass index, kg/m211.2 ± 4.012.1 ± 4.29.5 ± 3.0<0.001
 Body fat percentage39 ± 943 ± 832 ± 7<0.001
 Total body lean, kg44 ± 1238 ± 655 ± 10<0.001
 Fat-free mass index, kg/m215.9 ± 3.114.6 ± 2.018.3 ± 3.1<0.001
 Trunk fat, kg16 ± 616 ± 617 ± 60.18
 Appendicular fat, kg13 ± 615 ± 611 ± 4<0.001
 Appendicular lean, kg19 ± 616 ± 325 ± 4<0.001

Crude and adjusted clinical indicators of thigh fat and muscle measures.

Univariate analyses of the clinical indicators of thigh fat and muscle measures were determined (data available upon request from the author). Characteristics that yielded at least marginally significant associations in those analyses were carried into multivariable models (Table 2). When comodeled, older age, female sex, longer RA duration, higher tender joint count, and current prednisone use were all significantly and inversely associated with the TMA, while height was positively associated. Together, these 6 characteristics accounted for 47% of the variability in the TMA (adjusted R2 = 0.474), with the RA disease-related characteristics accounting for nearly 20% of the explainable variability (Table 2, TMA model 2). The other characteristics with significant or marginal associations with TMA in univariate models were no longer significantly associated in the multivariable model, and their exclusion did not meaningfully reduce the predictive ability of the model.

Table 2. Multivariable associations of thigh fat and muscle composition measures with characteristics of the study participants*
 Model 1Model 2
  • *

    CES-D = Center for Epidemiologic Studies Depression Scale; RA = rheumatoid arthritis; SE = shared epitope; IL-6 = interleukin-6; SHS = modified Sharp/van der Heijde score; VAS = visual analog scale; TV = television; RF = rheumatoid factor; anti-CCP = anti–cyclic citrullinated peptide; HCQ = hydroxychloroquine; MTX = methotrexate.

Thigh muscle area (cm2)    
 Age, per year−0.980.001−1.13<0.001
 Male sex22.90.00121.7<0.001
 Height, per meter56.30.08666.60.022
 Exercise, per 30 minutes0.620.55
 CES-D score, per unit−0.110.77
 Ever smoker1.750.72
 Current smoker5.130.55
 Thyroid disease1.270.83
 RA duration, per year−0.490.067−0.590.006
 Any SE alleles−4.480.38
 log IL-6, per log unit−2.360.30
 Square root swollen joint count−0.210.93
 Square root tender joint count−3.920.031−3.190.018
 log total SHS−0.890.62
 Pain (by VAS), per unit0.120.26
 Current prednisone use−15.40.007−15.80.001
 Total adjusted R20.4730.474
 R2 for RA characteristics0.076 (16% of total)0.090 (19% of total)
Thigh muscle density (mg/cm3)    
 Age, per year−0.120.003−0.13<0.001
 Male sex−0.210.82
 Height, per meter7.620.0986.900.024
 Any college1.530.0441.320.053
 Exercise, per 30 minutes−0.0030.99
 TV watching, per 30 minutes−0.120.21
 CES-D score, per unit0.0070.90
 Thyroid disease−0.670.41
 Diabetes mellitus−1.640.20
 RA duration, per year−0.040.25−0.060.060
 RF or anti-CCP0.720.34
 Any SE alleles−0.500.50
 log IL-6, per log unit−0.960.003−0.920.001
 Square root swollen joint count0.150.66
 Square root tender joint count−0.390.11−0.330.040
 log total SHS0.0080.97
 Pain (by VAS), per unit−0.0010.94
 Current prednisone use−3.72<0.001−3.48<0.001
 Current HCQ use1.690.0351.670.017
 Total adjusted R20.3810.414
 R2 for RA characteristics0.210 (55% of total)0.260 (63% of total)
Thigh fat area (cm2)    
 Male sex−45.6<0.001−55.8<0.001
 Height, per meter74.70.1795.90.059
 Exercise, per 30 minutes0.570.75
 RA duration, per year0.720.120.760.046
 log IL-6, per log unit−1.580.70
 Square root swollen joint count2.380.58
 Square root tender joint count0.240.94
 log total SHS1.840.55
 Pain (by VAS), per unit0.090.62
 Current prednisone use−28.30.003−23.40.006
 Current MTX use5.710.51
 Current biologic agent9.070.29
 Total adjusted R20.2010.222
 R2 for RA characteristics0.040 (20% of total)0.051 (23% of total)

For the TMD, all of the clinical indicators of the TMA except sex were also associated in the final adjusted model (Table 2, TMD model 2). In addition, higher IL-6 levels were significantly associated with a lower mean adjusted TMD; while participants prescribed hydroxychloroquine (HCQ) had a significantly higher mean adjusted TMD compared to nonusers. Together, the 8 characteristics modeled accounted for 41% of the variability in TMD, with 63% of the explainable variability deriving from RA-related characteristics. For the TFA, female sex, greater height, and longer RA duration were associated with a higher mean adjusted TFA, while the mean adjusted TFA was 23 cm2 lower in current prednisone users compared to nonusers (P = 0.006) (Table 2, TFA model 2). Together, these 4 characteristics accounted for only 20% of the variability in TFA, with RA-related characteristics accounting for 23% of the explainable variability.

Correlations between thigh composition measures.

TMD was positively correlated with TMA (Spearman's rho = 0.75, P < 0.001) but was not strongly correlated with the TFA (Spearman's rho = 0.13, P = 0.13). TMA and TFA were also uncorrelated (Spearman's rho = 0.06, P = 0.50). Despite a moderate-to-high correlation, the TMD and TMA were not sufficiently collinear to refute comodeling (mean VIF 2.40).

Crude and adjusted associations of thigh fat and muscle measures with functional outcomes and fatigue.

Crude and adjusted associations of the TFA, TMA, and TMD with scores on the HAQ, SF-36 physical functioning, SPPB, and FACIT instruments are summarized in Table 3. For each of the outcomes, higher TFA and lower TMA were significantly associated with higher reported disability and limitation in performance when only these two covariates were comodeled (model 1). Adding TMD to the model (model 2) supplanted nearly the entirety of the association of TMA with the outcomes and eliminated the statistical significance of the remaining TMA associations. In models including potential confounders (model 3), the magnitudes of the associations of TFA and TMD with the outcomes were reduced by 25–75%; however, these associations remained robust in the final models that included only the confounders that showed significant associations with the outcomes (model 4).

Table 3. Crude and adjusted associations of thigh composition measures with functional outcomes and fatigue*
 Model 1Model 2Model 3Model 4
  • *

    HAQ = Health Assessment Questionnaire; TFA = thigh fat area; TMA = thigh muscle area; TMD = thigh muscle density; RA = rheumatoid arthritis; IL-6 = interleukin-6; TJC = tender joint count; HCQ = hydroxychloroquine; SF-36 = Short Form 36 health survey; FACIT = Functional Assessment of Chronic Illness Therapy.

 TFA, per 10 cm20.044<0.0010.050<0.0010.050<0.0010.042<0.001
 TMA, per 10 cm2−0.072<0.001−0.0110.620.0180.50
 TMD, per mg/cm3−0.062<0.001−0.0470.014−0.041<0.001
 Age, per year−0.0020.74
 Male sex−0.1980.208
 Height, per meter−1.9150.003−1.130.018
 Any college−0.0370.73
 RA duration, per year0.0010.95
 log IL-6, per log unit0.0520.24
 Square root TJC0.122<0.0010.112<0.001
 Current prednisone use0.2170.0560.2230.044
 Current HCQ use−0.0870.44
SF-36 physical functioning        
 TFA, per 10 cm2−1.37<0.001−1.68<0.001−1.520.001−1.35<0.001
 TMA, per 10 cm22.16<0.001−0.720.40−1.870.093
 TMD, per mg/cm32.93<0.0012.320.0042.77<0.001
 Age, per year−0.060.83
 Male sex−6.990.28
 Height, per meter68.00.01054.30.014
 Any college−1.630.71
 RA duration, per year−0.110.59
 log IL-6, per log unit−1.680.36
 Square root TJC−4.39<0.001−4.21<0.001
 Current prednisone use−9.100.051−8.990.046
 Current HCQ use0.970.83
Short Physical Performance Battery        
 TFA, per 10 cm2−0.33<0.001−0.38<0.001−0.32<0.001−0.35<0.001
 TMA, per 10 cm20.58<0.0010.050.72−0.140.59
 TMD, per mg/cm30.54<0.0010.360.0070.43<0.001
 Age, per year−0.15<0.001−0.15<0.001
 Male sex0.700.52
 Height, per meter8.100.067
 Any college0.700.35
 RA duration, per year−0.020.48
 log IL-6, per log unit−0.620.047−0.620.045
 Square root TJC−0.370.080
 Current prednisone use−1.110.16
 Current HCQ use0.150.85
Square root FACIT score        
 TFA, per 10 cm20.0680.0020.0770.0010.0480.0650.0560.009
 TMA, per 10 cm2−0.0960.004−0.0170.740.0750.25
 TMD, per mg/cm3−0.0810.044−0.0840.070−0.0640.011
 Age, per year−0.0120.40
 Male sex−0.1890.62
 Height, per meter−1.6580.28
 Any college0.2970.25
 RA duration, per year0.0040.76
 log IL-6, per log unit0.0700.52
 Square root TJC0.296<0.0010.324<0.001
 Current prednisone use0.3690.18
 Current HCQ use−0.0110.97

Accordingly, in the final adjusted models, each 10 cm2 higher TFA was associated with a 0.042 unit higher HAQ score, a 1.35 unit lower SF-36 physical functioning score, a 0.35 unit lower SPPB score, and a 0.056 unit higher FACIT score (P < 0.01 for each comparison), while each mg/cm3 increase in the TMD was associated with a 0.041 unit lower HAQ score, a 2.77 unit higher SF-36 physical functioning score, a 0.43 unit higher SPPB score, and a 0.064 unit lower FACIT score (P < 0.05 for each comparison). The adjusted associations of the TFA and TMD with functional outcomes did not significantly differ by sex, and there was no statistical evidence for interaction between the TFA and TMD on any of the functional outcomes (data not shown).

Similar results were observed for the associations of the TFA and TMD with the proportion of obligatory VLAs affected (Table 4). Specifically, on average, each 10 cm2 higher TFA was associated with a 1.28 percentage point higher adjusted proportion of obligatory VLAs affected (P = 0.011), while each mg/cm3 higher TMD was associated with a 1.07 percentage point lower adjusted proportion (P = 0.024) (Table 4, obligatory VLA model 4). The TFA, but not the TMA or TMD, was significantly associated with the proportion of committed and discretionary VLAs affected, with each 10 cm2 higher TFA being associated with a 1.73 and 1.32 percentage point higher adjusted proportion of VLAs affected, respectively (P < 0.05 for each comparison) (Table 4, committed and discretionary VLA model 4).

Table 4. Crude and adjusted associations of thigh composition measures with affected valued life activities*
 Model 1Model 2Model 3Model 4
  • *

    VLAs = Valued Life Activities; TFA = thigh fat area; TMA = thigh muscle area; TMD = thigh muscle density; RA = rheumatoid arthritis; IL-6 = interleukin-6; TJC = tender joint count; HCQ = hydroxychloroquine.

Proportion of obligatory VLAs affected        
 TFA, per 10 cm21.450.0071.400.0091.660.0081.280.011
 TMA, per 10 cm2−2.670.001−1.690.0620.010.78
 TMD, per mg/cm3−1.280.010−1.190.021−1.070.024
 Height, per meter−5.680.17
 Age, per year0.590.0820.550.079
 Male sex2.510.74
 Any college−4.220.49
 RA duration, per year−0.170.55
 log IL-6, per log unit1.300.60
 Square root TJC7.18<0.0017.14<0.001
 Current prednisone use22.39<0.00121.90<0.001
 Current HCQ use−6.490.31
Proportion of committed VLAs affected        
 TFA, per 10 cm22.34<0.0012.32<0.0011.810.0111.730.002
 TMA, per 10 cm2−3.17<0.001−2.700.008−0.310.81−1.400.15
 TMD, per mg/cm3−0.610.32−0.250.68−0.380.52
 Height, per meter−6.330.12
 Age, per year0.370.34
 Male sex−6.680.44
 Any college3.210.64
 RA duration, per year0.100.75
 log IL-6, per log unit1.130.23
 Square root TJC8.51<0.0018.96<0.001
 Current prednisone use4.460.46
 Current HCQ use−8.990.22
Proportion of discretionary VLAs affected        
 TFA, per 10 cm21.800.0011.770.0011.460.0301.320.015
 TMA, per 10 cm2−2.690.001−2.310.014−0.370.77−1.280.17
 TMD, per mg/cm3−0.490.39−0.250.68−0.350.52
 Height, per meter−3.210.39
 Age, per year0.290.42
 Male sex−4.580.57
 Any college1.800.78
 RA duration, per year0.140.62
 log IL-6, per log unit0.080.38
 Square root TJC7.08<0.0017.21<0.001
 Current prednisone use4.020.48
 Current HCQ use−6.750.33

Correlations of other body composition measures with functional measures.

We compared the strength of correlation of CT-derived thigh composition measures with functional outcomes against those of anthropometric and DXA-derived measures of body composition (Table 5). In general, anthropometric parameters were not significantly correlated with functional outcomes. In the few cases of significant correlation of anthropometric parameters with functional outcomes (e.g., the BMI with SF-36 physical functioning and the proportion of VLAs affected), the strength of the correlation was weaker than that for the CT-derived measures. Among the DXA-derived measures of fat, the strength of the correlation of the fat mass index, body fat percentage, and appendicular fat with the functional outcomes was comparable or slightly higher than that for the TFA. Appendicular lean mass was the strongest DXA-derived measure, with comparable levels of correlation with functional outcomes as the TMA or TMD.

Table 5. Correlations of body composition measures with functional outcomes*
 HAQSF-36 physical functioningSPPBProportion of VLAs affected
  • *

    Correlations were calculated using Spearman's correlation coefficient (ρ). HAQ = Health Assessment Questionnaire; SF-36 = Short Form 36 health survey; SPPB = Short Physical Performance Battery; VLAs = Valued Life Activities; CT = computed tomography; DXA = dual x-ray absorptiometry.

Thigh CT–derived measures        
 Total thigh area, cm20.0370.65−0.0220.79−0.0010.990.0840.30
 Thigh muscle area, cm2−0.356<0.0010.285<0.0010.397<0.001−0.2650.001
 Thigh muscle density, mg/cm3−0.3530.373<0.0010.460<0.001−0.270<0.001<0.001
 Thigh fat area, cm20.327<0.001−0.2250.005−0.291<0.0010.307<0.001
Anthropometric parameters        
 Weight, kg−0.0800.320.0010.990.0500.540.0050.95
 Body mass index, kg/m20.1170.14−0.1760.027−0.1320.100.1990.012
 Waist circumference, cm0.0310.70−0.1200.13−0.1070.180.1170.14
 Waist-to-hip ratio−0.1660.0370.0490.540.1110.17−0.1350.091
DXA-derived measures        
 Total body fat, kg0.2510.001−0.2470.002−0.1890.0180.297<0.001
 Fat mass index, kg/m20.355<0.001−0.327<0.001−0.281<0.0010.381<0.001
 Body fat percentage0.460<0.001−0.369<0.001−0.362<0.0010.443<0.001
 Total body lean, kg−0.343<0.0010.2280.0040.271<0.001−0.2590.001
 Fat free mass index, kg/m2−0.223<0.0010.0970.2280.1360.089−0.1330.097
 Trunk fat, kg0.1550.052−0.1880.018−0.1170.1450.2130.007
 Appendicular fat, kg0.318<0.001−0.271<0.001−0.2590.0010.345<0.001
 Appendicular lean, kg−0.355<0.0010.2540.0010.311<0.001−0.272<0.001

We next explored the linearity of the associations of TMD and TFA with functional outcomes and the combined associations of TMD and TFA (Figure 1). For the HAQ, the change in HAQ score per quartile increase in the TMD or TFA was roughly linear in adjusted analyses (Figure 1A). The mean adjusted HAQ scores were 2-fold higher in the group with the lowest TMD (below the median of 39 mg/cm3) and the highest TFA (above the median of 113 cm2) as compared to the group with the highest TMD and the lowest TFA (1.18 versus 0.55 HAQ units; P < 0.001).

thumbnail image

Figure 1. Crude and adjusted individual and combined associations of thigh muscle density (TMD) and thigh fat area (TFA) with functional outcomes assessed by A, the Health Assessment Questionnaire (HAQ), B, the Short Physical Performance Battery (SPPB), and C, the Valued Life Activities (VLA) instruments. Depicted are crude and adjusted means with 95% confidence intervals. Adjustments are for model 4 covariates from Tables 3 and 4. The ranges of values for the TMD are 25.7–36.1 mg/cm3 for those in quartile 1 (Q1; n = 40), 36.2–38.9 mg/cm3 for those in quartile 2 (n = 36), 39.1–42.5 mg/cm3 for those in quartile 3 (n = 38), and 42.7–49.7 mg/cm3 for those in quartile 4 (n = 38). The ranges of values for the TFA are 22–88 cm2 for those in quartile 1 (n = 38), 89–112 cm2 for those in quartile 2 (n = 38), 113–148 cm2 for those in quartile 3 (n = 38), and 149–336 cm2 for those in quartile 4 (n = 38). High TMD plus low TFA represents participants in TMD quartile 3 or 4 and in TFA quartile 1 or 2 (n = 30). High TMD plus high TFA represents participants in TMD quartile 3 or 4 and in TFA quartile 3 or 4 (n = 46). Low TMD plus low TFA represents participants in TMD quartile 1 or 2 and in TFA quartile 1 or 2 (n = 46). Low TMD plus high TFA represents participants in TMD quartile 1 or 2 and in TFA quartile 3 or 4 (n = 30).

Download figure to PowerPoint

For the SPPB (Figure 1B), the mean adjusted scores were 79% higher for participants in the fourth quartile of the TMD as compared to those in the first quartile (14.3 versus 8.0 SPPB units; P < 0.001); however, the difference in the mean adjusted SPPB scores was the largest between the first and second quartiles of the TMD (8.0 versus 12.9 SPPB units; P < 0.01), and did not differ between the third and fourth quartiles. For the TFA, the mean adjusted SPPB scores were 25% higher for participants in the lowest TFA quartile as compared to those in the highest quartile (14.1 versus 9.8 SPPB units; P < 0.001). As with the TMD, the trend in SPPB scores across quartiles of TFA was not linear, as scores were not significantly lower until the third quartile of the TFA. The mean adjusted SPPB scores were 63% higher in the group with the highest TMD and lowest TFA as compared to the group with the lowest TMD and highest TFA (14.5 versus 8.9 SPPB units; P < 0.001).

For the proportion of obligatory VLAs affected (Figure 1C), per-quartile differences in the associations of the TMD and TFA with the outcome were roughly linear. The proportion of obligatory VLAs affected was 2.4-fold higher, on average, for the group with the lowest TMD and highest TFA as compared to the group with the highest TMD and lowest TFA (45% versus 19%; P = 0.002).


  1. Top of page
  2. Abstract
  7. Acknowledgements

In this investigation, which, to our knowledge, is the first to use mid-thigh quantitative CT to measure body composition in RA patients, we observed that the TMD, more so than the TMA and independently of the TFA, was a strong indicator of functional outcomes and physical performance, with each mg/cm3 increase in the TMD being associated with a lower HAQ score, a lower proportion of valued life activities affected, and higher SF-36 physical functioning and SPPB scores. Moreover, in multivariable analyses, RA disease features accounted for approximately one-fourth of the explainable variability in the TMA and TFA and three-fourths of the explainable variability in the TMD.

In recent years, CT-derived muscle density has been established as a marker of muscle quality (11). Density is estimated from CT-derived attenuation coefficients, and low muscle density reflects increased myocellular lipid content and fatty infiltration of the muscle compartment (10). Low muscle density at various sites has been associated with adverse outcomes in several studies of non-RA patients, including frailty (36), reduced physical performance (18–20), increased incidence of mobility limitations (21, 22), increased risk of hip fracture (37), and increased risk of hospitalization (18). However, until now, there have been no studies assessing muscle density in the RA population, let alone associations with functional outcomes. The findings of the present study confirm the importance of this measure in the RA population. Notably, muscle density was a stronger indicator of functional outcomes and physical performance than muscle area, anthropometric parameters, or DXA-derived measures of lean body mass or fat mass, a finding concordant with that of other studies in the general population (18, 37). It is interesting to note that in these studies, in which the enrolled patients were generally older than our cohort by an average of about a decade, the average thigh muscle area and muscle density were similar to those of our RA cohort (21).

Inflammatory cytokines, such as IL-6 and tumor necrosis factor, have been associated with reduced muscle density in non-RA populations (38, 39). Early studies by Roubenoff and colleagues showing reduced body cell mass in RA patients implicated inflammatory cytokines, suggesting a cytokine-driven state of hypermetabolism as the cause (6). Inflammation likely exerts multiple, complex effects on muscle, such as reduced insulin/growth factor sensitivity and accelerated protein degradation. Inflammatory cytokines are clearly associated with muscle wasting in several pathologic states, such as cancer, heart failure, and sepsis (40). Indeed, in our study, the IL-6 level was independently and inversely associated with muscle density and muscle area. In addition, use of HCQ and use of prednisone were also indicators of thigh muscle area and density. While HCQ has not been studied in this context, it is plausible that its effect on muscle density could be mediated by potentiating the activity of lipolytic enzymes by reducing their lysosomal degradation (41, 42), which could, hypothetically, lead to reduced intramyocellular lipid. However, since the association of HCQ with muscle density could be confounded by factors related to the indication for prescribing the drug (i.e., milder disease, etc.), additional study is needed to explore this association.

It was also notable that both fat and muscle areas were lower in prednisone users in our study. There may be several mechanisms underlying this finding. For one, prednisone-treated patients undergo an apparent redistribution of fat from the periphery to the trunk (43), and for another, glucocorticoid therapy may induce muscle wasting and has been associated with low muscle area (44). These indicators are potential targets for intervention that may improve muscle quality and functional outcomes.

The strong, independent association of lower muscle density and higher fat area with limitation in physical performance and disability suggest that these outcomes might be improved by interventions designed to increase muscle density and/or decrease fat. For example, it has been shown that in a study of non-RA patients, muscle area was the same or greater in obese individuals compared to non-obese controls, but muscle density was lower (45). When obese individuals participated in a 16-week weight loss program, there was an increase in muscle density (46), and other studies have shown that changes in muscle density parallel changes in strength during resistance detraining and retraining (13). From a functional standpoint, resistance exercises have already been shown to be effective in reducing pain and fatigue scores, as well as increasing strength and certain measures of physical performance in the RA population (47–50). However, as no studies in RA patients have used CT to determine body composition, the effects of exercise on muscle density in RA are still unknown. Although the duration of intentional exercise and sedentary activities was associated with some thigh composition measures in univariate analyses, we did not observe strong independent associations in multivariable models. This could indicate a true lack of association, or it may be a reflection of the imprecision of self-reported physical activity among RA patients. A clinical trial using a physical activity intervention would be preferred in order to clarify the role of physical activity in altering body composition in RA patients as a means of improving function.

In addition to CT, we also investigated two other methods of determining body composition: DXA and anthropometry. In general, the anthropometry results were poorly correlated with the functional outcome measures and essentially did not add to the information obtained via CT. Some DXA-derived measures of body composition, however, showed associations with functional outcomes similar to those of the CT-derived measures, and it would appear that appendicular lean mass and appendicular fat mass are potentially reasonable surrogates (9). In clinical practice, neither CT nor DXA is yet practical for use in measuring body composition. It is possible that other anthropometric parameters, such as thigh circumference or caliper skinfold assessment of thigh fat, could be a feasible surrogate for clinical practice; however, these were not evaluated in our study.

In our study, both a lower TMD and a higher TFA were significantly associated with a risk of affected obligatory VLAs, but the TMD was not associated with committed or discretionary VLAs. Obligatory VLAs are those considered necessary for survival and self-sufficiency, including walking to get around, getting around one's community by car or public transportation, and taking care of one's basic needs, such as bathing, washing, getting dressed, or taking care of personal hygiene (51). That these types of activities appear to be more strongly influenced by thigh composition than either committed or discretionary VLAs is intriguing. Since our study population was older and generally had more longstanding RA, it is plausible that our subjects have learned ways to participate in these activities despite their physical performance limitations, or they have already adapted and eliminated these from consideration as being important life activities.

The data from our study are cross-sectional, making these findings hypothesis-generating. Both a longitudinal, prospective cohort study of body composition and, eventually, a randomized controlled trial for interventions would be needed to confirm these postulations. Aside from the cross-sectional nature of our investigation, there are additional limitations. First, our study population was older, with relatively longstanding RA, and while a broad distribution of RA characteristics was represented, most had low-to-moderate disease activity with only mild-to-moderate disability. Second, our CT scans were regional, at only the mid thigh, which may provide a more limited estimate of whole body composition. Analysis of cross-sections from multiple body regions would be a useful future study. Third, we did not include measures of muscle strength, which would have permitted a more complete assessment of muscle quality.

In summary, 3 main conclusions can be drawn from this investigation. First, CT of the mid-thigh is a promising technique for directly assessing regional body composition in RA patients, allowing the determination of muscle area, fat area, and muscle density. Second, RA disease features play an important role in thigh composition, accounting for a large proportion of the explainable variability. Third and perhaps most important, muscle density appears to be a stronger indicator of physical functioning than muscle area in RA patients, with associations that are independent of fat mass. Further studies are needed to determine whether interventions aimed at increasing muscle density will improve the disability and poor physical performance that are so characteristic of this population.


  1. Top of page
  2. Abstract
  7. Acknowledgements

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Giles had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Fontaine, Bathon, Giles.

Acquisition of data. Kramer, Bathon, Giles.

Analysis and interpretation of data. Fontaine, Bathon, Giles.


  1. Top of page
  2. Abstract
  7. Acknowledgements

We would like to thank the staff of the Johns Hopkins Bayview Medical Center General Clinical Research Center, the field center of the Baltimore Multi-Ethnic Study of Atherosclerosis (MESA) cohort, and the MESA Coordinating Center at the University of Washington, Seattle. We are indebted to the dedication and hard work of ESCAPE RA staff members Marilyn Towns, Michelle Jones, Patricia Jones, Marissa Hildebrandt, Shawn Franckowiak, and Brandy Miles, as well as to the participants in the ESCAPE RA study who graciously agreed to take part in this research. Drs. Uzma Haque, Clifton Bingham III, Carol Ziminski, Jill Ratain, Ira Fine, Joyce Kopicky-Burd, David McGinnis, Andrea Marx, Howard Hauptman, Achini Perera, Peter Holt, Alan Matsumoto, Megan Clowse, Gordon Lam, and others generously recommended their patients for this study. We would especially like to thank Dr. Luigi Ferrucci for providing the equipment and expertise required to analyze the thigh CT scans in the study.


  1. Top of page
  2. Abstract
  7. Acknowledgements
  • 1
    Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000; 29: 30520.
  • 2
    Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006; 56: 1827.
  • 3
    Farragher TM, Lunt M, Bunn DK, Silman AJ, Symmons DP. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007; 66: 48692.
  • 4
    Morris A, Yelin EH, Panopalis P, Julian L, Katz PP. Long-term patterns of depression and associations with health and function in a panel study of rheumatoid arthritis. J Health Psychol 2011; 16: 66777.
  • 5
    Luyster FS, Chasens ER, Wasko MC, Dunbar-Jacob J. Sleep quality and functional disability in patients with rheumatoid arthritis. J Clin Sleep Med 2011; 7: 4955.
  • 6
    Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis: possible association with tumor necrosis factor. J Rheumatol 1992; 19: 150510.
  • 7
    Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M, et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 2008; 59: 80715.
  • 8
    Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M, et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010; 62: 317382.
  • 9
    Giles JT, Bartlett SJ, Andersen RE, Fontaine KR, Bathon JM. Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthritis Rheum 2008; 59: 140715.
  • 10
    Goodpaster BH, Thaete FL, Kelley DE. Composition of skeletal muscle evaluated with computed tomography. Ann N Y Acad Sci 2000; 904: 1824.
  • 11
    Mattsson S, Thomas BJ. Development of methods for body composition studies. Phys Med Biol 2006; 51: R20328.
  • 12
    Overend TJ, Cunningham DA, Paterson DH, Lefcoe MS. Thigh composition in young and elderly men determined by computed tomography. Clin Physiol 1992; 12: 62940.
  • 13
    Taaffe DR, Henwood TR, Nalls MA, Walker DG, Lang TF, Harris TB. Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults. Gerontology 2009; 55: 21723.
  • 14
    Heymsfield SB, Olafson RP, Kutner MH, Nixon DW. A radiographic method of quantifying protein-calorie undernutrition. Am J Clin Nutr 1979; 32: 693702.
  • 15
    Pietrobelli A, Wang Z, Heymsfield SB. Techniques used in measuring human body composition. Curr Opin Clin Nutr Metab Care 1998; 1: 43948.
  • 16
    Strandberg S, Wretling ML, Wredmark T, Shalabi A. Reliability of computed tomography measurements in assessment of thigh muscle cross-sectional area and attenuation. BMC Med Imaging 2010; 10: 18.
  • 17
    Abbatecola AM, Ferrucci L, Ceda G, Russo CR, Lauretani F, Bandinelli S, et al. Insulin resistance and muscle strength in older persons. J Gerontol A Biol Sci Med Sci 2005; 60: 127882.
  • 18
    Cawthon PM, Fox KM, Gandra SR, Delmonico MJ, Chiou CF, Anthony MS, et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J Am Geriatr Soc 2009; 57: 14119.
  • 19
    Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M, Stamm E, et al. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the Health, Aging and Body Composition study. J Am Geriatr Soc 2002; 50: 897904.
  • 20
    Hicks GE, Simonsick EM, Harris TB, Newman AB, Weiner DK, Nevitt MA, et al. Cross-sectional associations between trunk muscle composition, back pain, and physical function in the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci 2005; 60: 8827.
  • 21
    Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 2005; 60: 32433.
  • 22
    McDermott MM, Ferrucci L, Guralnik J, Tian L, Liu K, Hoff F, et al. Pathophysiological changes in calf muscle predict mobility loss at 2-year follow-up in men and women with peripheral arterial disease. Circulation 2009; 120: 104855.
  • 23
    Giles JT, Szklo M, Post W, Petri M, Blumenthal RS, Lam G, et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther 2009; 11: R36.
  • 24
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 25
    Giles JT, Allison M, Bingham CO III, Scott WM Jr, Bathon JM. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2009; 61: 124856.
  • 26
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 27
    Haley SM, McHorney CA, Ware JE Jr. Evaluation of the MOS SF-36 Physical Functioning Scale (PF-10): I. Unidimensionality and reproducibility of the Rasch item scale. J Clin Epidemiol 1994; 47: 67184.
  • 28
    Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49: M8594.
  • 29
    Katz PP. The impact of rheumatoid arthritis on life activities. Arthritis Care Res 1995; 8: 2728.
  • 30
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 31
    Van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 2634.
  • 32
    Blair SN. How to assess exercise habits and physical fitness. In: Matarazzo JD, Weiss SM, Herd JA, Miller NE, editors. Behavioral health: a handbook of health enhancement and disease prevention. New York: John Wiley & Sons; 1984. p. 4247.
  • 33
    Sheehan TJ, Fifield J, Reisine S, Tennen H. The measurement structure of the Center for Epidemiologic Studies Depression Scale. J Pers Assess 1995; 64: 50721.
  • 34
    Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 8119.
  • 35
    Kobayashi H, Giles JT, Polak JF, Blumenthal RS, Leffell MS, Szklo M, et al. Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific. J Rheumatol 2010; 37: 7309.
  • 36
    Cesari M, Leeuwenburgh C, Lauretani F, Onder G, Bandinelli S, Maraldi C, et al. Frailty syndrome and skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin Nutr 2006; 83: 11428.
  • 37
    Lang T, Cauley JA, Tylavsky F, Bauer D, Cummings S, Harris TB, et al. Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the Health, Aging, and Body Composition study. J Bone Miner Res 2010; 25: 5139.
  • 38
    Toth MJ, Ades PA, Tischler MD, Tracy RP, LeWinter MM. Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure. Int J Cardiol 2006; 109: 17987.
  • 39
    McDermott MM, Ferrucci L, Guralnik JM, Tian L, Green D, Liu K, et al. Elevated levels of inflammation, d-dimer, and homocysteine are associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial disease. J Am Coll Cardiol 2007; 50: 897905.
  • 40
    Pajak B, Orzechowska S, Pijet B, Pijet M, Pogorzelska A, Gajkowska B, et al. Crossroads of cytokine signaling—the chase to stop muscle cachexia. J Physiol Pharmacol 2008; 59 Suppl 9: 25164.
  • 41
    Severson DL, Lefebvre FA, Sloan SK. Effect of chloroquine on rates of lipolysis in the isolated perfused rat heart and in rat epididymal fat pads. J Mol Cell Cardiol 1980; 12: 97792.
  • 42
    Minor LK, Mahlberg FH, Jerome WG, Lewis JC, Rothblat GH, Glick JM. Lysosomal hydrolysis of lipids in a cell culture model of smooth muscle foam cells. Exp Mol Pathol 1991; 54: 15971.
  • 43
    Engvall IL, Brismar K, Hafstrom I, Tengstrand B. Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study. Scand J Rheumatol 2011; 40: 1618.
  • 44
    Horber FF, Scheidegger JR, Grunig BE, Frey FJ. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest 1985; 15: 3027.
  • 45
    Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 2000; 49: 46772.
  • 46
    Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999; 48: 83947.
  • 47
    Rall LC, Roubenoff R. Body composition, metabolism, and resistance exercise in patients with rheumatoid arthritis [review]. Arthritis Care Res 1996; 9: 1516.
  • 48
    Hakkinen A, Pakarinen A, Hannonen P, Kautiainen H, Nyman K, Kraemer WJ, et al. Effects of prolonged combined strength and endurance training on physical fitness, body composition and serum hormones in women with rheumatoid arthritis and in healthy controls. Clin Exp Rheumatol 2005; 23: 50512.
  • 49
    Marcora SM, Lemmey AB, Maddison PJ. Can progressive resistance training reverse cachexia in patients with rheumatoid arthritis? Results of a pilot study. J Rheumatol 2005; 32: 10319.
  • 50
    Strasser B, Leeb G, Strehblow C, Schobersberger W, Haber P, Cauza E. The effects of strength and endurance training in patients with rheumatoid arthritis. Clin Rheumatol 2011; 30: 62332.
  • 51
    Katz P, Morris A, Yelin E. Subclinical disability in valued life activities among individuals with rheumatoid arthritis. Arthritis Rheum 2008; 59: 141623.